Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Neurological disorders

Cannabinoids have limited impact on MS symptoms

Following a systematic review and meta-analysis researchers have concluded that cannabinoids have limited therapeutic effect on symptoms of multiple sclerosis

Cannabinoids have limited efficacy in improving the symptoms of multiple sclerosis (MS), authors of a systematic review and meta-analysis have concluded[1].

Reporting their results in JAMA Network Open (12 October 2018), the researchers used data from 17 randomised controlled trials looking at the effects of oral or oromucosal medicinal cannabinoids involving a total of 3,161 patients with MS.

They found that the effect of cannabinoid treatment on subjectively measured spasticity, pain and bladder dysfunction was mild compared with placebo. There was no significant impact on objectively measured spasticity.

Active treatment was associated with an increased risk of adverse events (rate ratio 1.72 patient-years; 95% confidence interval, 1.46-2.02 patient-years). However, the risk of serious adverse events was not significantly different to placebo, leading the researchers to conclude the drugs could be considered safe.

“To our knowledge, this is the most complete systematic review and meta-analysis of the effect of cannabinoids on MS,” the researchers wrote.

“Our results show limited therapeutic efficacy of cannabinoids for the primary outcomes of spasticity, pain, and bladder dysfunction in patients with MS.”

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20205824

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.